New developments in therapy for colorectal cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Colorectal cancer remains a significant cause of cancer death, and its treatment is the subject of active, ongoing investigation within all treatment modalities, including surgery, chemotherapy, and radiotherapy. In this review we discuss selected interesting and important research findings since the year 2000 and comment on their potential impact on the adjuvant and advanced disease management of patients with colon and rectal cancer.
Supplementary Material (0)
- Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23–47. CrossRef
- Nelson H, Petrelli N, Carlin A, et al.: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001, 93:583–596. These NCI evidence-based guidelines outline surgical standards for colorectal cancer resection with the intent to reduce surgical variability and improve comparisons across clinical trials. CrossRef
- Weeks JC, Nelson H, Gelber S, et al.: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002, 287:321–328. CrossRef
- Schrag D, Cramer LD, Bach PB, et al.: Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 2000, 284:3028–3035. CrossRef
- Tepper JE, O’Connell MJ, Niedzwiecki D, et al.: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001, 19:157–163.
- Stocchi L, Nelson H, Sargent DJ, et al.: Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001, 19:3895–3902.
- Hodgson DC, Fuchs CS, Ayanian JZ: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 2001, 93:501–515. CrossRef
- Heald RJ, Moran BJ, Ryall RD, et al.: Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 1998, 133:894–899. CrossRef
- Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638–646. This randomized trial of short-course preoperative radiotherapy in patients who receive a TME demonstrates the favorable local control achieved by TME alone as well as the additional benefit of preoperative radiotherapy in reducing local recurrence. A survival benefit was not demonstrated in this early analysis at 2-year follow-up. CrossRef
- Tepper JE, O’Connell M, Niedzwiecki D, et al.: Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control: final report of Intergroup 0114. J Clin Oncol 2002, 20:1744–1750. CrossRef
- Riethmuller G, Holz E, Schlimok G, et al.: Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: sevenyear outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788–1794.
- Punt CJ, Nagy A, Douillard JY, et al.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002, 360:671–677. CrossRef
- Fields AL, Keller AM, Schwartzberg L, et al.: Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study [abstract]. Proc ASCO 2002, 21:508.
- Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349–1355.
- Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999, 17:1356–1363.
- Buyse M, Piedbois P: Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001, 28(Suppl 1):20–24. CrossRef
- Schrag D, Rifas-Shiman S, Saltz L, et al.: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002, 20:3999–4005. CrossRef
- NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444–1450. CrossRef
- Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials.Lancet 2001, 358:1291–1304. The results of this meta-analysis from 13 preoperative trials and eight postoperative trials support the benefit of adjuvant radiotherapy in reducing local recurrence. The greatest benefit was seen in preoperative radiotherapy at a biologically effective dose of greater than 30 Gy.
- Roh M, Petrelli N, Wiend S, et al.: Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03) [abstract]. Proc ASCO 2001, 20:490.
- FongY: Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999, 49:231–255.
- Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039–2048. CrossRef
- Goldberg RM: Adjuvant therapy after resection of liver-limited colorectal cancer metastases.ASCO 2000 Clinical Practice Forum; 2000:73–77.
- Gryfe R, Kim H, Hsieh ET, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69–77. CrossRef
- Jen J, Kim H, Piantadosi S, et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994; 331:213–221. CrossRef
- Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196–1206. This report identified retention of 18q alleles in MSS disease and mutation of the TGF-β RII in MSI-H disease to be associated with improved survival after adjuvant chemotherapy. CrossRef
- Salonga D, Danenberg KD, Johnson M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322–1327.
- Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001, 85:827–830. CrossRef
- AllegraC: Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002, 20:1711–1713. CrossRef
- Elsaleh H, Joseph D, Grieu F, et al.: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355:1745–1750. CrossRef
- Ribic CM, Sargent D, Moore MJ, et al.: Tumor microsatellite instability (MSI) and the benefit of 5-FU based chemotherapy in stage II and III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials [abstract]. Proc ASCO 2002, 21:509a.
- Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905–914. CrossRef
- Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041–1047. CrossRef
- de GramontA, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.
- Goldberg RM, Morton RF, Sargent D, et al.: N9741 Oxaliplatin (oxal) or CPT-11 +5-fluorouracil(5FU)/leucovorin(LV) or oxal + CPT11 in advanced colorectal cancer (CRC): initial toxicity and response data from a GI Intergroup study [abstract]. Proc ASCO 2002, 21:511a.
- Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345:144–146. CrossRef
- Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801–3807.
- Douillard JY, Hoff PM, Skillings J, et al.: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20:3605–3616. CrossRef
- Carmichael J, Popiela T, Radstone D, et al.: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20:3617–3627. CrossRef
- Van CutsemE, Sorensen JL, Cassidy J, et al.: International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus LV in the treatment of advanced colorectal cancer [abstract]. Proc ASCO 2001, 20:523a.
- Hoff PM, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282–2292. One of two randomized phase III trials of oral capecitabine versus 5-fluorouracil. See annotation for following reference.
- Van CutsemE, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097–4106. These two randomized phase III trials demonstrate equivalent tumor response, disease-free survival, and overall survival for capecitabine with a more favorable toxicity profile.
- Saltz L, Meropol NJ, Loehrer PJ, et al.: Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract]. Proc ASCO 2002, 21:504a.
- Bergsland E, Hurwitz H, Fehrenbacher L, et al.: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin to FU/LV alone in patients with metastatic colorectal cancer [abstract]. Proc ASCO 2000, 19:939a.
- Gianotonio BJ, Levy D, Catalano PJ, et al.: Incorporating angiongenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer: a toxicity analysis of ECOG study E2200 [abstract]. Proc ASCO 2002, 21:503a.
- Colorectal Cancer Collaborative Group:Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000, 356:968–974. CrossRef
- Schrag D, Cramer LD, Bach PB, Begg CB: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93:850–857. CrossRef
- Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091–1097. This pooled analysis confirms that elderly patients receive the same benefit from adjuvant therapy as their younger counterparts with similar toxicity. CrossRef
About this Article
- New developments in therapy for colorectal cancer
Current Oncology Reports
Volume 5, Issue 3 , pp 183-191
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links